Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

Ag­ile Ther­a­peu­tics is start­ing to get testy af­ter suf­fer­ing yet an­oth­er snub from the FDA, an­nounc­ing this morn­ing that it sim­ply doesn’t agree with the reg­u­la­tors’ as­ser­tion that its con­tra­cep­tion patch is faulty.

The com­pa­ny is strap­ping on box­ing gloves over the mat­ter, as the FDA’s re­quests could sink the com­pa­ny fi­nan­cial­ly — un­less it finds new ways to cov­er the bills.

Ag­ile’s once-week­ly, low-dose con­tra­cep­tive patch called Twirla is a com­bi­na­tion hor­mon­al patch that con­tains ethinyl estra­di­ol and lev­onorgestrel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER